DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Bardoxolone methyl is an investigational drug.
There have been 29 clinical trials for Bardoxolone methyl. The most recent clinical trial was a Phase 2 trial, which was initiated on April 18th 2017.
The most common disease conditions in clinical trials are Kidney Diseases, Renal Insufficiency, Chronic, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Reata Pharmaceuticals, Inc., Kyowa Kirin Co., Ltd., and NYU Langone Health.
There are forty-four US patents protecting this investigational drug and two hundred and fifty-eight international patents.
Recent Clinical Trials for Bardoxolone methyl
|A Phase 2 Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression (MERLIN)||Reata Pharmaceuticals, Inc.||Phase 2|
|BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)||Reata Pharmaceuticals, Inc.||Phase 2/Phase 3|
|BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)||NYU Langone Health||Phase 2/Phase 3|
Top disease conditions for Bardoxolone methyl
Top clinical trial sponsors for Bardoxolone methyl
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Bardoxolone methyl||Start Trial||Methods for the prevention and the treatment of rapidly progressive glomerulonephritis||INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) UNIVERSITE PARIS DESCARTES (Paris, FR)||Start Trial|
|Bardoxolone methyl||Start Trial||Oxidative retinal diseases||Retrotope, Inc. (Los Altos, CA)||Start Trial|
|Bardoxolone methyl||Start Trial||Impaired energy processing disorders and mitochondrial deficiency||Retrotope, Inc. (Los Altos, CA)||Start Trial|
|Bardoxolone methyl||Start Trial||Antioxidant Inflamation modulators: oleanolic acid derivatives with amino and other modifications at C-17||REATA PHARMACEUTICALS, INC. (Irving, TX)||Start Trial|
|Bardoxolone methyl||Start Trial||Disorders implicating PUFA oxidation||Retrotope, Inc. (Los Altos, CA)||Start Trial|
|Bardoxolone methyl||Start Trial||Neurodegenerative disorders and muscle diseases implicating PUFAs||Retrotope, Inc. (Los Altos, CA)||Start Trial|
|Bardoxolone methyl||Start Trial||Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof||vTv Therapeutics LLC (High Point, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Bardoxolone methyl||World Intellectual Property Organization (WIPO)||WO2016071727||2034-11-04||Start Trial|
|Bardoxolone methyl||Australia||AU2012249921||2031-04-26||Start Trial|
|Bardoxolone methyl||Canada||CA2834341||2031-04-26||Start Trial|
|Bardoxolone methyl||Denmark||DK2701697||2031-04-26||Start Trial|
|Bardoxolone methyl||European Patent Office||EP2701697||2031-04-26||Start Trial|
|Bardoxolone methyl||European Patent Office||EP3689342||2031-04-26||Start Trial|
|Bardoxolone methyl||Israel||IL229017||2031-04-26||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|